A microdose of GLP-1 (glucagon-like peptide-1) is an informal, non-standard term referring to the administration of GLP-1 receptor agonist medications at doses substantially lower than those licensed and recommended by UK regulatory authorities such as the MHRA (Medicines and Healthcare products Regulatory Agency) and NICE (National Institute for Health and Care Excellence)
If dizziness persists despite these interventions, contact your PlexusDx provider to discuss dose reduction or a slower titration schedule
Sorafenib causes the production of P62, which inhibits NRF2 degradation and promotes the inactivation of KEAP1, followed by the activation of heme oxygenase-1 (HO-1), quinone oxidoreductase-1, and ferritin heavy chain-1, which enhances NRF2 nuclear localization
Key Background Researchers have studied for years whether GLP-1 drugs could reduce bone density, after previous studies suggested people with obesity and type 2 diabetes likely have less bone mass
It can result from oxidative stress, inflammation, heavy metal toxicity, poor circulation, and mitochondrial dysfunction
